Naveglitazar
Based on 1 Customer Validation
Naveglitazar (LY519818) is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.47%
- CAS No.: 476436-68-7
- Formule: C25H26O6
- Masse moléculaire:422.47
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Naveglitazar, a non-thiazolidinediones (TZD), functions as a potent and efficacious insulin sensitizer in rodents, possessing a novel profile that may result in an improved therapeutic agent for the treatment of type 2 diabetes and associated dyslipidemia. The extent of in vitro binding of [3H]Naveglitazar to plasma proteins is evaluated by ultracentrifugation in mouse, rat, and monkey plasma. The mean percentages±S.E.M. of protein binding of radioactivity in plasma over the concentration range of 0.1 to 1000 ng/ml after in vitro incubation at 37°C for 60 min are 99.5%±0.1% (mice), 99.6%±0.1% (rat), and 99.6%±0.3% (monkey). These results show that Naveglitazar is highly bound to plasma proteins among the species examined, and binding is independent of concentration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 476436-68-7
-
Appearance Solid
-
Masse moléculaire 422.47
-
Formule C25H26O6
-
Color Off-white to light yellow
-
SMILES
O=C(O)[C@@H](OC)CC1=CC=C(OCCCOC2=CC=C(OC3=CC=CC=C3)C=C2)C=C1
-
Synonyms
LY519818
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protocole
The single-dose plasma pharmacokinetics of Naveglitazar, LY591026, and radioactivity are studied in male ICR mice, and male Fischer 344 rats after oral administration of [14C]Naveglitazar. A separate study is conducted in rats to evaluate the pharmacokinetics of Naveglitazar and LY591026 after the administration of a single 10 mg/kg dose of each compound. Mice and rats are administered a 10 mg/kg oral dose of [14C]Naveglitazar with a specific activity of 50 μCi/kg[1].
Mice[1]
Mice are divided into three groups. Group 1 animals (n=3 per time point) are housed in shoebox cages and are used to determine the pharmacokinetics of Naveglitazar, LY591026, and radioactivity. Blood samples are collected for plasma from mice via cardiac puncture at 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, and 120 h postdose. Group 2 mice are housed in metabolism cages (n=3 per cage) for the collection of excreta to determine the mass balance and metabolism of Naveglitazar. Urine, feces, and cage wash are collected in 24 h intervals for up to 120 h. The third group of animals (n=3 per time point) are housed in shoebox cages and used to evaluate the metabolites present in plasma.
Rat[1]
Rats are divided into three groups. Group 1 animals (n=3 per time point) are housed in shoebox cages and are used to determine the pharmacokinetics of Naveglitazar, LY591026, and radioactivity. Blood samples are collected for plasma from rats via cardiac puncture at 0.5, 1, 2, 4, 8, 12, 24, 48, and 72 h postdose. Group 2 rats (n=4) are individually housed in metabolism cages for the collection of excreta to determine the mass balance and metabolism of Naveglitazar. Urine, feces, and cage wash are collected in 24 h intervals for up to 120 h. Group 3 animals, which are bile-cannulated rats (n=4), are individually housed in metabolism cages for the collection of excreta to determine the mass balance and metabolism of Naveglitazar. Urine, feces, and cage wash are collected in 24 h intervals for up to 72 h, whereas bile is collected in 8-h intervals. In a separate study, rats are given Naveglitazar or LY591026. In this study, blood samples for plasma are collected at 0.5, 1, 2, 4, 8, 12, and 24 h to determine pharmacokinetics of each analyte.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Naveglitazar Related Classifications
HY-U00036A Related Classifications
Powered by Bioz